CONCLUDING REMARKS

Tat displays pleiotropic properties, and blocking exogenous Tat might interfere with the development of immunodeficiency. Several studies, however, have shown controversial effects, and it is sometimes difficult to reconcile the experimental observations.

ACKNOWLEDGMENTS

We are grateful to Herve Lecoeur and Etienne Jacotot (Theraptosis, Paris) for helpful comments on the manuscript and for generating the results shown in Figure 9.2 and Figure 9.3.

REFERENCES

1. Ameisen, J.C., Estaquier, J., Idziorek, T., and De Bels, F., Programmed cell death and AIDS pathogenesis: significance and potential mechanisms, Curr. Top. Microbiol. Immunol., 200, 195-211, 1995.

2. Roshal, M., Zhu, Y., and Planelles, V., Apoptosis in AIDS, Apoptosis, 6, 103-116, 2001.

3. Dianzani, U., Bensi, T., Savarino, A., Sametti, S., Indelicato, M., Mesturini, R., and Chiocchetti, A., Role of FAS in HIV infection, Curr.

4. Castedo, M., Perfettini, J.L., Andreau, K., Roumier, T., Piacentini, M., and Kroemer, G., Mitochondrial apoptosis induced by the HIV-1 envelope, Ann. N.Y. Acad. Sci., 1010, 19-28, 2003.

5. Seelamgari, A., Maddukuri, A., Berro, R., de la Fuente, C., Kehn, K., Deng, L., Dadgar, S., Bottazzi, M.E., Ghedin, E., Pumfery, A., and Kashanchi, F., Role of viral regulatory and accessory proteins in HIV-1 replication, Front. Biosci. 9, 2388-2413, 2004.

6. Opi, S., Peloponese, J.M. Jr, Esquieu, D., Campbell, G., de Mareuil, J., Walburger, A., Solomiac, M., Gregoire, C., Bouveret, E., Yirrell, D.L., and Loret E.P., Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants, J. Biol. Chem., 277, 35915-35919, 2002.

7. Frankel, A.D., Biancalana, S., and Hudson, D., Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. U.S.A., 86, 7397-7401, 1989.

8. Wrenger, S., Hoffmann, T., Faust, J., Mrestani-Klaus, C., Brandt, W., Neubert, K., Kraft, M., Olek,

S., Frank, R., Ansorge, S., and Reinhold, D., The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth, J. Biol. Chem., 272, 30283-30288, 1997.

9. Albini, A., Ferrini, S., Benelli, R., Sforzini, S., Giunciuglio, D., Aluigi, M.G., Proudfoot, A.E., Alouani,

S., Wells, T.N., Mariani, G., Rabin, R.L., Farber, J.M., and Noonan, D.M., HIV-1 Tat protein mimicry of chemokines, Proc. Natl. Acad. Sci. U.S.A., 95, 13153-13158, 1998.

10. Boykins, R.A., Mahieux, R., Shankavaram, U.T., Gho, Y.S., Lee, S.F., Hewlett, I.K., Wahl, L.M., Kleinman, H.K., Brady, J.N., Yamada, K.M., and Dhawan, S., A short polypeptide domain of HIV- 1-Tat protein mediates pathogenesis, J. Immunol., 163, 15-20, 1999.

11. Wrenger, S., Reinhold, D., Faust, J., Mrestani-Klaus, C., Brandt, W., Fengler, A., Neubert, K., and Ansorge, S., Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth, Adv.

12. Betti, M., Voltan, R., Marchisio, M., Mantovani, I., Boarini, C., Nappi, F., Ensoli, B., and Caputo, A., Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application, Vaccine, 19, 3408-3419, 2001.

13. Poggi, A., Carosio, R., Spaggiari, G.M., Fortis, C., Tambussi, G., Dell'Antonio, G., Dal Cin, E., Rubartelli, A., and Zocchi, M.R., NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain, J. Immunol., 168, 95-101, 2002.

14. Benelli, R., Barbero, A., Ferrini, S., Scapini, P., Cassatella, M., Bussolino, F., Tacchetti, C., Noonan, D.M., and Albini, A., Human immunodeficiency virus transactivator protein (Tat) stimulates chemo­taxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis, J. Infect. Dis., 182, 1643-1651, 2000.

15. Rossi, C., Balboni, P.G., Betti, M., Marconi, P.C., Bozzini, R., Grossi, M.P., Barbanti-Brodano, G., and Caputo, A., Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients, Gene Ther., 4, 1261-1269, 1997.

16. Kiernan, R.E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, H., Maudoux, F., Calomme, C., Burny, A., Nakatani, Y., Jeang, K.T., Benkirane, M., and Van Lint, C., HIV-1 tat transcriptional activity is regulated by acetylation, EMBO J., 18, 6106-6118, 1999.

17. Ott, M., Schnolzer, M., Garnica, J., Fischle, W., Emiliani, S., Rackwitz, H.R., and Verdin, E., Acety­lation of the HIV-1 Tat protein by p300 is important for its transcriptional activity, Curr. Biol., 9, 1489-1492, 1999.

18. Kaechlcke, K., Dorr, A., Hetzer-Egger, C., Kiermer, V., Henklein, P., Schnoelzer, M., Loret, E., Cole, P.A., Verdin, E., and Ott, M., Acetylation of Tat defines a cyclin T1-independent step in HIV trans­activation, Mol.

19. Green, M., Ishino, M., and Loewenstein, P.M., Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression, Cell, 58, 215-223, 1989.

20. Chaloin, O., Peter, J.-C., Briand, J.-P., Masquida, B., Desgranges, C., Muller, S., and Hoebeke, J., The N-terminus of HIV-1 Tat protein is essential for Tat-TAR RNA interaction, Cell. Mol. Life Sci., 62, 355-361, 2005.

21. Brigati, C., Giacca, M., Noonan, D.M., and Albini, A., HIV Tat, its TARgets and the control of viral gene expression, FEMS Microbiol. Lett., 220, 57-65, 2003.

22. Huigen, M.C., Kamp, W., and Nottet, H.S., Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection, Eur. J. Clin. Invest., 34, 57-66, 2004.

23. Barillari, G., Gendelman, R., Gallo, R.C., and Ensoli, B., The Tat protein of human immunode­ficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence, Proc. Natl. Acad. Sci. U.S.A., 90, 7941-7945, 1993.

24. Zauli, G., Gibellini, D., Celeghini, C., Mischiati, C., Bassini, A., La Placa, M., and Capitani, S., Pleiotropic effects of immobilized vs. soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes, J. Immunol., 157, 2216-2224, 1996.

25. Hamy, F., Gelus, N., Zeller, M., Lazdins, J.L., Bailly, C., and Klimkait, T., Blocking HIV replication by targeting Tat protein, Chem. Biol., 7, 669-676, 2000.

26. Fulcher, A.J. and Jans, D.A., The HIV-1 Tat transactivator protein: a therapeutic target? IUBMB Life, 55, 669-680, 2003.

27. Holmes, S.C., Arzumanov, A.A., and Gait, M.J., Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2-O- methyl G-clamp ribonucleoside analogues, Nucleic Acids Res., 31, 2759-2768, 2003.

28. Bai, J., Sui, J., Zhu, R.Y., Tallarico, A.S., Gennari, F., Zhang, D., and Marasco, W.A., Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies, J. Biol. Chem., 278, 1433-1442, 2003.

29. Tikhonov, I., Ruckwardt, T.J., Berg, S., Hatfield, G.S., and Pauza, C.D., Furin cleavage of the HIV- 1 Tat protein, FEBS Lett, 565, 89-92, 2004.

30. Ensoli, B., Buonaguro, L., Barillari, G., Fiorelli, V., Gendelman, R., Morgan, R.A., Wingfield, P., and Gallo, R.C., Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation, J. Virol., 67, 277-287, 1993.

31. Westendorp, M.O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K.M., and Krammer, P.H., Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120, Nature, 375, 497-500, 1995.

32. Chang, H.C., Samaniego, F., Nair, B.C., Buonaguro, L., and Ensoli, B., HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region, AIDS, 11, 1421-1431, 1997.

33. Frankel, A.D. and Pabo, C.O., Cellular uptake of the Tat protein from human immunodeficiency virus, Cell, 55, 1189-1193, 1988.

34. Westendorp, M.O., Li-Weber, M., Frank, R.W., and Krammer, P.H., Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells, J. Virol., 68, 4177-4185, 1994.

35. Rusnati, M. and Presta, M., HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies, Angiogenesis, 5, 141-151, 2002.

36. Li, C.J., Ueda, Y., Shi, B., Borodyansky, L., Huang, L., Li, Y.Z., and Pardee, A.B., Tat protein induces self-perpetuating permissivity for productive HIV-1 infection, Proc. Natl. Acad. Sci. U.S.A., 94, 8116-8120, 1997.

37. Huang, L., Bosch, I., Hofmann, W., Sodroski, J., and Pardee, A.B., Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage­tropic and T-lymphotropic HIV-1 strains, J.

38. Secchiero, P., Zella, D., Capitani, S., Gallo, R.C., and Zauli, G., Extracellular HIV-1 Tat protein up­regulates the expression of surface CXC-chemokine receptor 4 in resting CD4⁺ T cells, J. Immunol., 162, 2427-2431, 1999.

39. Viscidi, R.P., Mayur, K., Lederman, H.M., and Frankel, A.D., Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1, Science, 246, 1606-1608, 1989.

40. Meyaard, L., Otto, S.A., Schuitemaker, H., and Miedema, F., Effects of HIV-1 Tat protein on human T cell proliferation, Eur J. Immunol., 22, 2729-2732, 1992.

41. Li, C.J., Friedman, D.J., Wang, C., Metelev, V., and Pardee, A.B., Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein, Science, 268, 429-431, 1995.

42. Belliard, G., Romieu, A., Zagury, J.-F., Dali, H., Chaloin, O., Le Grand, R., Loret, E., Briand,

J.-P., Roques, B., Desgranges, C., and Muller, S., Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals, Vaccine, 21, 3186-3199, 2003.

43. Lecoeur, H., Chalouin, O., Briere, J.-J., Rebouillat, D., Langonne, A., Longin, C., Deniaud, A., Brenner, C., Briand, J.P., Muller, S., Rustin, P., and Jacoto, E., HIV-1 Tat induces inner and out mitochondrial membrane permeabilization in isolated mitochondria and inactivates cytochrome C oxydase. Submitted.

44. Nath, A. and Geiger, A., Neurobiological aspects of human immunodeficiency virus infection: neu­rotoxic mechanisms, Prog. Neurobiol., 54, 19-33, 1998.

45. Singh, I.N., Goody, R.J., Dean, C., Ahmad, N.M., Lutz, S.E., Knapp, P.E., Nath, A., and Hauser, K.F., Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: differential involvement of caspase-3 and endonuclease G, J. Neurovirol., 10, 141-151, 2004.

46. Li-Weber, M., Laur, O., Dern, K., and Krammer, P.H., T cell activation-induced and HIV tat-enhanced CD95(APO-1∕Fas) ligand transcription involves NF-kappaB, Eur J. Immunol., 30, 661-670, 2000.

47. Westendorp, M.O., Shatrov, V.A., Schulze-Osthoff, K., Frank, R., Kraft, M., Los, M., Krammer, P.H., Droge, W., and Lehmann, V., HIV-1 Tat potentiates TNF-induced NF-B activation and cytotoxicity by altering the cellular redox state, EMBO J., 14, 546-554, 1995.

48. Chen, D., Wang, M., Zhou, S., and Zhou, Q., HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim, EMBO J., 21, 6801-6810, 2002.

49. Sastry, K.J., Marin, M.C., Nehete, P.N., McConnell, K., el-Naggar, A.K., and McDonnell, T.J., Expression of human immunodeficiency virus type I Tat results in down-regulation of Bcl-2 and induction of apoptosis in hematopoietic cells, Oncogene, 13, 487-493, 1996.

50. Zauli, G., Gibellini, D., Caputo, A., Bassini, A., Negrini, M., Monne, M., Mazzoni, M., and Capitani,

S., The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells, Blood, 86, 3823-3834, 1995.

51. Bartz, S.R. and Emerman, M., Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8, J. Virol., 73, 1956-1963, 1999.

52. Macho, A., Calzado, M.A., Jimenez-Reina, L., Ceballos, E., Leon, J., and Munoz, E., Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms, Oncogene, 18, 7543-7551, 1999.

53. Purvis, S.F., Jacobberger, J.W., Sramkoski, R.M., Patki, A.H., and Lederman, M.M., HIV type 1 Tat protein induces apoptosis and death in Jurkat cells, AIDS Res. Hum. Retroviruses, 11, 443-450, 1995.

54. McCloskey, T.W., Ott, M., Tribble, E., Khan, S.A., Teichberg, S., Paul, M.O., Pahwa, S., Verdin, E., and Chirmule, N., Dual role of HIV Tat in regulation of apoptosis in T cells, J. Immunol., 158, 1014-1019, 1997.

55. Gibellini, D., Re, M.C., Ponti, C., Maldini, C., Celeghini, C., Cappellini, A., La Placa, M., and Zauli, G., HIV-1 Tat protects CD4⁺ Jurkat T lymphoblastoid cells from apoptosis mediated by TNF-related apoptosis-inducing ligand, Cell Immunol., 207, 89-99, 2001.

56. Katsikis, P.D., Garcia-Ojeda, M.E., Torres-Roca, J.F., Greenwald, D.R., Herzenberg, L.A., and Herzen- berg, L.A., HIV type 1 Tat protein enhances activation—but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals, Int. Immunol., 9, 835-841, 1997.

57. Park, I.W., Ullrich, C.K., Schoenberger, E., Ganju, R.K., and Groopman, J.E., HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation, J. Immunol., 167, 2766-2771, 2001.

58. Krone, W.J., Debouck, C., Epstein, L.G., Heutink, P., Meloen, R., and Goudsmit, J., Natural antibodies to HIV-Tat epitopes and expression of HIV-1 genes in vivo, J. Med. Virol., 26, 261-270, 1988.

59. McPhee, D.A., Kemp, B.E., Cumming, S., Stapleton, D., Gust, I.D., and Doherty, R.R., Recognition of envelope and Tat protein synthetic peptide analogs by HIV positive sera or plasma, FEBS Lett., 233, 393-396, 1988.

60. Tahtinen, M., Ranki, A., Valle, S.L., Ovod, V., and Krohn, K., B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains, Biomed. Pharmacother., 51, 480-487, 1997.

61. Demirhan, I., Chandra, A., Hasselmayer, O., Biberfeld, P., and Chandra, P., Detection of distinct patterns of anti-Tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma, J. Acquir. Immune Defic. Syndr., 22, 364-368, 1999.

62. Re, M.C., Vignoli, M., Furlini, G., Gibellini, D., Colangeli, V., Vitone, F., and La Placa, M., Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients, J. Clin. Virol., 21, 81-89, 2001.

63. Rodman, T.C., Pruslin, F.H., To, S.E., and Winston, R., Human immunodeficiency virus (HIV) Tat- reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identifi­cation of the epitope, J. Exp. Med., 175, 1247-1253, 1992.

64. Rodman, T.C., To, S.E., Hashish, H., and Manchester, K., Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein, Proc. Natl. Acad. Sci. U.S.A., 90, 7719-7723, 1993.

65. Re, M.C., Furlini, G., Vignoli, M., Ramazzotti, E., Zauli, G., and La Placa, M., Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients, Clin. Diagn. Lab. Immunol., 3, 230-232, 1996.

66. Zagury, J.F., Sill, A., Blattner, W., Lachgar, A., Le Buanec, H., Richardson, M., Rappaport, J., Hendel, H., Bizzini, B., Gringeri, A., Carcagno, M., Criscuolo, M., Burny, A., Gallo, R.C., and Zagury, D., Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine, J. Hum. Virol., 1, 282-292, 1998.

67. Rodman, T.C., Sullivan, J.J., Bai, X., and Winston, R., The human uniqueness of HIV: innate immunity and the viral Tat protein, Hum. Immunol., 60, 631-639, 1999.

68. Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M.T., Goletti, D., Baroncelli, S., Pace, M., Sernicola, L., Koanga-Mogtomo, M.L., Betti, M., Borsetti, A., Belli, R., Akerblom, L., Corrias, F., Butto, S., Heeney, J., Verani, P., Titti, F., and Ensoli, B., Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine, Nat. Med., 5, 643-650, 1999.

69. Cafaro, A., Caputo, A., Maggiorella, M.T., Baroncelli, S., Fracasso, C., Pace, M., Borsetti, A., Sernicola, L., Negri, D.R., Ten Haaft, P., Betti, M., Michelini, Z., Macchia, I., Fanales-Belasio, E., Belli, R., Corrias, F., Butto, S., Verani, P., Titti, F., and Ensoli, B., SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine, J. Med. Primatol., 29, 193-208, 2000.

70. Goldstein, G., Manson, K., Tribbick, G., and Smith, R., Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/ human immunodeficiency virus (SHIV33), Vaccine, 18, 2789-2795, 2000.

71. Pauza, C.D., Trivedi, P., Wallace, M., Ruckwardt, T.J., Le Buanec, H., Lu, W., Bizzini, B., Burny, A., Zagury, D., and Gallo, R.C., Vaccination with Tat toxoid attenuates disease in simian/ HIV-challenged macaques, Proc. Natl. Acad. Sci. U.S.A., 97, 3515-3519, 2000.

72. Richardson, M.W., Mirchandani, J., Silvera, P., Regulier, E.G., Capini, C., Bojczuk, P.M., Hu, J., Gracely, E.J., Boyer, J.D., Khalili, K., Zagury, J.F., Lewis, M.G., and Rappaport, J., Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses, DNA Cell. Biol., 21, 637-651, 2002.

73. Silvera, P., Richardson, M.W., Greenhouse, J., Yalley-Ogunro, J., Shaw, N., Mirchandani, J., Khalili,

K., Zagury, J.F., Lewis, M.G., and Rappaport, J., Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein, J. Virol., 76, 3800-3809, 2002.

74. Belliard, G., Hurtrel, B., Moreau, E., Lafont, B.A.P., Monceaux, V., Roques, B., Desgranges, C. Aubertin, A.-M., Le Grand, R., and Muller, S., Tat-neutralizing vs. Tat-protecting antibodies in Rhesus macaques vaccinated with Tat peptides, Vaccine, 23, 1399-407, 2005.

75. Tosi, G., Meazza, R., De Lerma Barbaro, A., D’Agostino, A., Mazza, S., Corradin, G., Albini, A., Nooman, D.M., Ferrini, S., and Accolla, R.S., Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR, Eur. J. Immunol., 30, 1120-1126, 2000.

76. Marinaro, M., Riccomi, A., Rappuoli, R., Pizza, M., Fiorelli, V., Tripiciano, A., Cafaro, A., Ensoli, B., and De Magistris, M.T., Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies cytotoxic T lymphocytes and mucosal IgA, Vaccine, 21, 3972-3981, 2003.

77. Tikhonov, I., Ruckwardt, T.J., Hatfield, G.S., and Pauza, C.D., Tat-neutralizing antibodies in vaccinated macaques, J. Virol., 77, 3157-3166, 2003.

78. Ruckwardt, T.J., Tikhonov, I., Berg, S., Hatfield, G.S., Chandra, A., Chandra, P., Gilliam, B., Redfield, R.R., Gallo, R.C., and Pauza, C.D., Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein, J. Virol., 78, 13190-13196, 2004.

79. Goldstein, G., Tribbick, G., and Manson, K., Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains, Vaccine, 19, 1738-1746, 2001.

80. Moreau, E., Belliard, G., Partidos, C.D., Pradezinsky, F., Le Buanec, H., Muller, S., and Desgranges, C., Important B cell epitopes for Tat-neutralisation in the serum samples of humans and different animal species immunised with Tat protein or Tat peptides, J. Gen. Virol., 85, 2893-2901, 2004.

81. Moreau, E., Hoebeke, J., Zagury, D., Muller, S., and Desgranges, C., Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficient virus type 1 Tat antigen, J. Virol., 78, 3792-3796, 2004.

82. Fanales-Belasio, E., Moretti, S., Nappi, F., Barillari, G., Micheletti, F., Cafaro, A., and Ensoli, B., Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses, J. Immunol., 168, 197-206, 2002.

83. Gavioli, R., Gallerani, E., Fortini, C., Fabris, M., Bottoni, A., Canella, A., Bonaccorsi, A., Marastoni, M., Micheletti, F., Cafaro, A., Rimessi, P., Caputo, A., and Ensoli, B., HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity, J. Immunol., 173, 3838-3843, 2004.

84. Gringeri, A., Santagostino, E., Muca-Perja, M., Mannucci, P.M., Zagury, J.-F., Bizzini, B., Lachgar, A., Carcagno, M., Rappaport, J., Criscuolo, M., Blattner, W., Burny, A., Gallo, R.C., and Zagury, D., Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients, J. Hum. Virol., 1, 293-298, 1998.

85. Gringeri, A., Santagostino, E., Muca-Perja, M., Le Buanec, H., Bizzini, B., Lachgar, A., Zagury, J.-F., Rappaport, J., Burny, A., Gallo, R.C., and Zagury, D., Tat toxoid as a component of a preventive vaccine in seronegative subjects, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 20, 371-375, 1999.

86. Fanales-Belasio, E., Cafaro, A., Cara, A., Negri, D.R., Fiorelli, V., Butto, S., Moretti, S., Maggiorella, M.T., Baroncelli, S., Michelini, Z., Tripiciano, A., Sernicola, L., Scoglio, A., Borsetti, A., Ridolfi, B., Bona, R., Ten Haaft, P., Macchia, I., Leone, P., Pavone-Cossut, M.R., Nappi, F., Vardas, E., Magnani, M., Laguardia, E., Caputo, A., Titti, F., and Ensoli, B., HIV-1 Tat-based vaccines: from basic science to clinical trials, DNA Cell. Biol., 21, 599-610, 2002.

87. Caputo, A., Gavioli, R., and Ensoli, B., Recent advances in the development of HIV-1 Tat-based vaccines, Curr. HIV Res., 2, 357-376, 2004.

88. Marasco, W.A., LaVecchio, J., and Winkler, A., Human anti-HIV-1 Tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS, J. Immunol. Methods, 231, 223-238, 1999.

89. Poznansky, M.C., La Vecchio, J., Silva-Arietta, S., Porter-Brooks, J., Brody, K., Olszak, I.T., Adams, G.B., Ramstedt, U., Marasco, W.A., and Scadden, D.T., Inhibition of human immunodeficiency virus replication and growth advantage of CD4⁺ T cells and monocytes derived from CD34⁺ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat, Hum. Gene Ther., 10, 2505-2514, 1999.